Pressure BioSciences Inc.

Pressure BioSciences PCT platform could play pivotal role in improving cancer diagnosis

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive Investors that scientists from Australia’s Centre for the Proteome of Human Cancer (ProCan) have published a recommended proteomic sample preparation protocol built around its Barocycler instrument system, based around Pressure Bio’s proprietary pressure cycling technology (PCT) platform, which may help to identify and use new cancer biomarkers.

In addition to this, Schumacher has filed a Form 4 with the SEC, and Schumacher says he's purchased shares of stock to show good faith in the company. Schumacher will hold an investor conference call 4:30PM Wednesday.

Quick facts: Pressure BioSciences Inc.

Price: $1.96

Market: OTCQB
Market Cap: $3.8 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences Inc. named herein, including the promotion by the Company of Pressure BioSciences Inc. in any Content on the Site, the...



Pressure BioSciences gets first customer for its BaroShear water soluble CBD...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive Investors the medical device company has won the first customer for its water-soluble CBD manufacturing system, the BaroShear K45. Schumacher explains the contract, worth $200,000, is with a company called Nano CBD...

3 weeks, 5 days ago

2 min read